CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: PRPF3 (ImmuneEditome ID:9129)

1. Gene summary of enriched editing regions for PRPF3

check button Gene summary
Gene informationGene symbol

PRPF3

Gene ID

9129

GeneSynonymsHPRP3|HPRP3P|PRP3|Prp3p|RP18|SNRNP90
GeneCytomap

1q21.2

GeneTypeprotein-coding
GeneDescriptionU4/U6 small nuclear ribonucleoprotein Prp3|PRP3 pre-mRNA processing factor 3 homolog|U4/U6 snRNP 90 kDa protein|U4/U6-associated RNA splicing factor|pre-mRNA-splicing factor 3
GeneModificationdate20230517
UniprotIDO43395
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr1:150339116-150341918:+ENST00000324862.6ENSG00000117360.11PRPF3exonicMER3,AluSp,AluJb,AluJo,FLAM_C,AluSx,AluSq2chr1:150339116-150341918:+.alignment
chr1:150342172-150343206:+ENST00000493553.1ENSG00000117360.11PRPF3ncRNA_exonicAluY,AluSx,FLAM_C,AluSc,(AC)nchr1:150342172-150343206:+.alignment
chr1:150346813-150348774:+ENST00000470824.1ENSG00000117360.11PRPF3ncRNA_exonic(ATAC)n,(ACAC)n,AluSx1,AluSq,MER47A,AluJb,AluSxchr1:150346813-150348774:+.alignment
chr1:150350728-150352599:+ENST00000467329.4ENSG00000117360.11PRPF3ncRNA_intronicAluSg,(T)n,AluJr,AluJb,AluYchr1:150350728-150352599:+.alignment
chr1:150350728-150352599:+ENST00000470824.1ENSG00000117360.11PRPF3ncRNA_intronicAluSg,(T)n,AluJr,AluJb,AluYchr1:150350728-150352599:+.alignment


Top

2. Tumor-specific enriched editing regions for PRPF3


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr1:150346813-150348774:+BRCAEER4.2063e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
ENSG00000117360.11,PRPF3KIRPEAG4.4425e-022.8288e-021.2927e+03image

Top

3. Enriched editing regions and immune related genes for PRPF3


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for PRPF3


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000117360.11,PRPF3
ESCAEAGIRENSG00000051009.6chr116214709:6214911:6217370:6217417-0.42746.3845e-031.1670e-06-0.4301imageNADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_MTORC1_SIGNALING
ENSG00000117360.11,PRPF3
ESCAEAGIRENSG00000079805.12chr1910809207:10809415:10812263:10812300-0.20032.7420e-025.8754e-06-0.4318imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184DNM2T_cells_gamma_deltaGSVA_HALLMARK_PANCREAS_BETA_CELLS

More results



Top

5. Enriched editing regions and immune infiltration for PRPF3


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr1:150346813-150348774:+BLCAEERT_cells_CD4_memory_resting3.7544e-02-0.3146image
ENSG00000117360.11,PRPF3BLCAEAGNK_cells_activated2.9421e-020.2837image
chr1:150346813-150348774:+BRCAEERT_cells_CD84.7555e-020.1046image
chr1:150350728-150352599:+BRCAEERT_cells_gamma_delta3.0496e-020.2707image
ENSG00000117360.11,PRPF3CESCEAGB_cells_memory8.9209e-03-0.3464image
ENSG00000117360.11,PRPF3COADEAGDendritic_cells_activated9.3884e-030.4740image
chr1:150339116-150341918:+ESCAEERB_cells_naive3.8828e-02-0.2475image
chr1:150346813-150348774:+ESCAEERT_cells_gamma_delta5.6849e-030.2760image
ENSG00000117360.11,PRPF3ESCAEAGT_cells_gamma_delta1.9298e-040.3367image
chr1:150346813-150348774:+GBMEERMacrophages_M21.8452e-02-0.2938image
ENSG00000117360.11,PRPF3GBMEAGMacrophages_M21.3819e-02-0.3040image
chr1:150346813-150348774:+KIRCEERT_cells_CD4_naive3.1296e-030.2898image
chr1:150350728-150352599:+KIRCEERPlasma_cells2.3997e-020.3656image
ENSG00000117360.11,PRPF3KIRCEAGT_cells_CD4_naive1.8025e-030.2930image
chr1:150346813-150348774:+KIRPEERT_cells_CD4_memory_resting4.4028e-02-0.2702image
ENSG00000117360.11,PRPF3KIRPEAGT_cells_CD4_memory_resting1.3354e-02-0.3231image
chr1:150346813-150348774:+LGGEERMast_cells_activated6.1388e-030.2100image
ENSG00000117360.11,PRPF3LGGEAGMast_cells_activated4.2928e-030.2143image
chr1:150339116-150341918:+LUADEERMast_cells_resting2.2872e-020.3837image
chr1:150346813-150348774:+LUSCEERMacrophages_M22.2818e-02-0.2425image
ENSG00000117360.11,PRPF3LUSCEAGMacrophages_M25.9305e-03-0.2747image
chr1:150339116-150341918:+OVEERT_cells_CD4_memory_activated2.3038e-060.7928image
chr1:150346813-150348774:+OVEERMast_cells_activated3.4622e-040.2752image
chr1:150350728-150352599:+OVEERDendritic_cells_activated1.9529e-030.4542image
ENSG00000117360.11,PRPF3OVEAGMacrophages_M01.3788e-03-0.2367image
ENSG00000117360.11,PRPF3PAADEAGMacrophages_M13.8327e-03-0.5200image
chr1:150346813-150348774:+PCPGEERMonocytes5.7839e-040.6505image
ENSG00000117360.11,PRPF3PCPGEAGMonocytes8.0516e-040.6161image
chr1:150346813-150348774:+PRADEERT_cells_CD83.9542e-020.3843image
ENSG00000117360.11,PRPF3PRADEAGMonocytes1.8820e-02-0.3312image
chr1:150346813-150348774:+SKCMEERB_cells_memory3.3575e-030.5181image
chr1:150339116-150341918:+STADEERMast_cells_activated3.4187e-030.2476image
chr1:150346813-150348774:+STADEERT_cells_CD87.7949e-040.2933image
chr1:150350728-150352599:+STADEERB_cells_memory1.2462e-020.4506image
ENSG00000117360.11,PRPF3STADEAGMast_cells_activated2.2729e-020.1602image
chr1:150346813-150348774:+THCAEERT_cells_CD84.0428e-020.3138image
ENSG00000117360.11,PRPF3THCAEAGMonocytes8.6478e-030.3605image
ENSG00000117360.11,PRPF3THYMEAGDendritic_cells_resting4.4391e-02-0.3828image
ENSG00000117360.11,PRPF3UCECEAGT_cells_gamma_delta2.1335e-020.4331image


Top

6. Enriched editing regions and immune gene sets for PRPF3


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr1:150346813-150348774:+BRCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEER7.7558e-070.2573image
ENSG00000117360.11,PRPF3BRCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.0330e-060.2482image
chr1:150339116-150341918:+BRCAGSVA_HALLMARK_SPERMATOGENESISEER1.6703e-020.3717image
ENSG00000117360.11,PRPF3CESCGSVA_HALLMARK_NOTCH_SIGNALINGEAG2.1060e-03-0.4024image
chr1:150346813-150348774:+CESCGSVA_HALLMARK_NOTCH_SIGNALINGEER8.3228e-03-0.3930image
ENSG00000117360.11,PRPF3COADGSVA_HALLMARK_SPERMATOGENESISEAG1.5089e-02-0.4469image
ENSG00000117360.11,PRPF3ESCAGSVA_HALLMARK_HYPOXIAEAG1.4351e-040.3430image
chr1:150339116-150341918:+ESCAGSVA_HALLMARK_GLYCOLYSISEER7.0477e-030.3193image
chr1:150346813-150348774:+ESCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER4.4826e-020.2021image
chr1:150346813-150348774:+GBMGSVA_HALLMARK_ADIPOGENESISEER3.9240e-020.2584image
ENSG00000117360.11,PRPF3GBMGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG3.4432e-020.2628image
chr1:150346813-150348774:+KIRCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.2893e-020.2455image
ENSG00000117360.11,PRPF3KIRCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.2506e-020.2364image
chr1:150346813-150348774:+KIRPGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER1.1049e-020.3372image
ENSG00000117360.11,PRPF3KIRPGSVA_HALLMARK_COAGULATIONEAG7.2575e-030.3490image
chr1:150346813-150348774:+LGGGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER8.2557e-050.2981image
ENSG00000117360.11,PRPF3LGGGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG2.1346e-040.2756image
ENSG00000117360.11,PRPF3LIHCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG2.3859e-02-0.4693image
chr1:150346813-150348774:+LUADGSVA_HALLMARK_P53_PATHWAYEER3.9860e-020.1607image
chr1:150346813-150348774:+LUSCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER6.9487e-030.2858image
ENSG00000117360.11,PRPF3LUSCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.3687e-020.2471image
ENSG00000117360.11,PRPF3OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG8.6755e-070.3570image
chr1:150339116-150341918:+OVGSVA_HALLMARK_FATTY_ACID_METABOLISMEER4.3653e-030.5503image
chr1:150346813-150348774:+OVGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.0746e-070.3994image
chr1:150350728-150352599:+OVGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER3.8383e-03-0.4271image
ENSG00000117360.11,PRPF3PAADGSVA_HALLMARK_MTORC1_SIGNALINGEAG4.9484e-02-0.3680image
chr1:150346813-150348774:+PAADGSVA_HALLMARK_MYC_TARGETS_V2EER1.5850e-03-0.5879image
ENSG00000117360.11,PRPF3PRADGSVA_HALLMARK_MYOGENESISEAG2.1860e-02-0.3237image
chr1:150346813-150348774:+PRADGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER4.4464e-020.3759image
ENSG00000117360.11,PRPF3SKCMGSVA_HALLMARK_G2M_CHECKPOINTEAG2.1867e-02-0.3759image
chr1:150339116-150341918:+STADGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER1.0165e-040.3248image
ENSG00000117360.11,PRPF3STADGSVA_HALLMARK_HYPOXIAEAG3.4430e-070.3494image
chr1:150346813-150348774:+STADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER2.1081e-020.2037image
chr1:150350728-150352599:+STADGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.5164e-020.4392image
ENSG00000117360.11,PRPF3TGCTGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG1.5591e-020.5204image
ENSG00000117360.11,PRPF3THCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG3.1359e-02-0.2989image
ENSG00000117360.11,PRPF3THYMGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.8182e-020.4432image
ENSG00000117360.11,PRPF3UCECGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG9.5555e-040.5898image


Top

7. Enriched editing regions and drugs for PRPF3


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr1:150339116-150341918:+BRCABicalutamideEER2.7625e-02-0.3440image
chr1:150346813-150348774:+BRCAGSK269962AEER4.2398e-04-0.1856image
ENSG00000117360.11,PRPF3BRCABMS.509744EAG2.3878e-03-0.1560image
ENSG00000117360.11,PRPF3CESCAKT.inhibitor.VIIIEAG1.6807e-020.3183image
chr1:150346813-150348774:+CESCA.770041EER3.4827e-03-0.4311image
ENSG00000117360.11,PRPF3COADKIN001.135EAG3.3298e-02-0.3963image
chr1:150346813-150348774:+ESCACCT018159EER1.4076e-04-0.3734image
ENSG00000117360.11,PRPF3ESCABexaroteneEAG4.8725e-04-0.3162image
chr1:150339116-150341918:+ESCABryostatin.1EER3.6682e-03-0.3428image
ENSG00000117360.11,PRPF3GBMABT.888EAG8.4544e-030.3240image
chr1:150346813-150348774:+GBMABT.888EER7.4485e-030.3315image
ENSG00000117360.11,PRPF3KIRCAG.014699EAG1.3629e-020.2335image
chr1:150350728-150352599:+KIRCGSK.650394EER6.9504e-03-0.4307image
chr1:150346813-150348774:+KIRCJNK.Inhibitor.VIIIEER4.5269e-030.2789image
ENSG00000117360.11,PRPF3KIRPBortezomibEAG9.1512e-03-0.3394image
chr1:150346813-150348774:+KIRPLenalidomideEER1.9704e-020.3109image
ENSG00000117360.11,PRPF3LAMLDasatinibEAG4.6592e-020.2478image
chr1:150346813-150348774:+LGGAZD6482EER6.6576e-040.2592image
ENSG00000117360.11,PRPF3LGGAZ628EAG5.7831e-03-0.2072image
ENSG00000117360.11,PRPF3LIHCLapatinibEAG5.8174e-030.5803image
chr1:150346813-150348774:+LUSCJW.7.52.1EER1.2476e-04-0.3977image
ENSG00000117360.11,PRPF3LUSCJW.7.52.1EAG1.2176e-04-0.3767image
ENSG00000117360.11,PRPF3OVBMS.536924EAG1.0523e-07-0.3837image
chr1:150339116-150341918:+OVBexaroteneEER2.4391e-030.5787image
chr1:150346813-150348774:+OVCCT007093EER5.4425e-070.3783image
chr1:150350728-150352599:+OVEmbelinEER4.0143e-040.5103image
ENSG00000117360.11,PRPF3PAADDoxorubicinEAG1.0300e-020.4689image
chr1:150346813-150348774:+PAADJW.7.52.1EER1.0046e-020.4955image
ENSG00000117360.11,PRPF3PCPGLapatinibEAG5.8358e-030.5255image
chr1:150346813-150348774:+PCPGLapatinibEER1.4597e-020.4920image
chr1:150346813-150348774:+PRADA.770041EER5.7419e-04-0.6004image
ENSG00000117360.11,PRPF3PRADBexaroteneEAG2.1140e-020.3253image
ENSG00000117360.11,PRPF3SKCMGefitinibEAG9.0518e-03-0.4289image
chr1:150346813-150348774:+SKCMBI.D1870EER3.8004e-030.5123image
chr1:150350728-150352599:+STADGW.441756EER6.9025e-030.4827image
chr1:150339116-150341918:+STADBexaroteneEER5.4174e-03-0.2356image
ENSG00000117360.11,PRPF3STADBexaroteneEAG8.5301e-04-0.2329image
chr1:150346813-150348774:+STADJNK.9LEER2.6173e-040.3174image
ENSG00000117360.11,PRPF3TGCTJNK.Inhibitor.VIIIEAG5.6115e-030.5823image
ENSG00000117360.11,PRPF3THCABAY.61.3606EAG2.2405e-020.3162image
chr1:150346813-150348774:+THYMMG.132EER1.2595e-020.5115image
ENSG00000117360.11,PRPF3THYMA.770041EAG1.4539e-040.6571image
ENSG00000117360.11,PRPF3UCECBI.D1870EAG1.8720e-02-0.4414image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType